Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...

UNITY Biotechnology (UBX) announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...